Purpose. Dorzolamide is the first carbonic anhydrase inhibitor (CAI) for the treatment of glaucoma. In addition to the established hypotensive effects, CAI agents have also been reported to have some vasuactive effects. The ocular hemodynamic effects of Dorzolamide had yet to be investigated. This study investigated the effects on retinal and epipapillary circulation following acute application. Methods. In a double-masked placebo-controlled cross-over design, intraocular pressure (IOP) and scanning laser video fluorescein angiography were evaluated in 13 normal subjects at baseline and 2 hours following application. Results. The drug hastened arteriovenous passage time (p<0.05; 18%) and accelerated capillary blood velocities in the macula (p<0.05; 16%) and the superficial optic nervehead (p<0.05; 15%) while remaining arterial and venous diameters unaffected. The placebo failed to alter these measures. IOP also decreased significantly from 15.7 ±0.7 to 13.7 ±0.7 mmHg (p<0.01; 22%) after the acute application. Conclusion. Dorzolamide caused an acute significant increase in retinal and superficial optic nervehead circulation. These results suggests that Dorzolamide could benefit patients with ocular vascular illness characterized by vascular insufficiency.
|Original language||English (US)|
|Journal||Investigative Ophthalmology and Visual Science|
|State||Published - Feb 15 1996|
ASJC Scopus subject areas
- Sensory Systems
- Cellular and Molecular Neuroscience